Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

To determine the rate of disease control of the combination of 9-ING-41 and retifanlimab plus gemcitabine/nab-paclitaxel in patients with pancreatic cancer without prior systemic therapy for

  • 0 views
  • 23 Mar, 2022
  • 1 location
Actuate 1901: 9-ING-41 in Myelofibrosis

9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study

cancer
ruxolitinib
neutrophil count
stem cell transplantation
  • 23 views
  • 13 May, 2022
  • 9 locations
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

of the study drugs involved in this study are: 9-ING-41 Losartan Ferumoxytol FOLFIRINOX (made up of 4 different drugs): 5-Fluorouracil (5-FU

  • 0 views
  • 17 Jun, 2022
  • 1 location
9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β

solid tumors
measurable disease
neutrophil count
paclitaxel
metastatic malignancy
  • 795 views
  • 29 May, 2022
  • 10 locations
9-ING-41 in Pediatric Patients With Refractory Malignancies.

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

monoclonal antibodies
myelosuppressive chemotherapy
myelosuppression chemotherapy
germ cell tumors
brain stem tumor
  • 0 views
  • 14 May, 2022
  • 8 locations
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names

biological factors
monoclonal antibodies
neutrophil count
cancer
carboplatin
  • 0 views
  • 21 Oct, 2022
  • 2 locations